ERBB2 and cancer: By an autocrine mechanism, it has been demonstrated that the SP released from cancer cells induced the growth of tumors [37] and that this autocrine action promotes persistent human epidermal growth factor receptor 2 (HER2) activation, leading to drug resistance and malignant progression [38].